Sven Karlsson

Syenex is a synbio technology company that provides novel delivery vector to genetic medicine developers. Our goal is to make it easier for developers to design, test, and scale curative cell and gene therapies

Venture For America is a national nonprofit and two-year Fellowship program that gives recent college graduates firsthand startup experiences to help them become strong leaders. Fellows learn important startup skills at Training Camp, apply for jobs within our company network, and work for two years as full-time, salaried employees in one of 13 cities. When Fellows are ready to start a company — be it two years after college or nine — VFA has the resources (like a crowdfunding competition and accelerator) to help make that dream a reality. Our vision: Venture For America is creating an accessible and inclusive future of entrepreneurship in America.

PanelClaw provides solar flat roof mounting solutions to accelerate the adoption of photovoltaics worldwide. As the market share leader in flat roof mounting solutions for PV solar systems, our racking has been deployed on over 12,000 projects, totaling more than 2.5 Gigawatts in 48 US states, Puerto Rico, the Caribbean and more than 35 other countries around the world. The clawFR product platform, our 5th flat roof platform in 15 years epitomizes our innovation DNA and is transforming the way flat roof PV is designed and deployed. It offers faster build speed through no-tool module installation and a single bolt hardware kit. clawFR is available in single and dual tilt, with multiple spacing options including an 11” inter-row spacing 10-degree configuration which offers the highest power density in the industry. The clawFR platform is a semi-rigid rail-based system, which allows for optimal ballast and mechanical attachment placement. With intelligent O&M features, clawFR delivers the reliability you have come to expect from PanelClaw. ClawFR, paired with clawOS, the most advanced racking design and engineering digital package, delivers unbeatable life-cycle value to our partners. With PanelClaw, our partners always experience A to Z project support. Beginning with the initial inquiry, we guide our customers through product selection, design reviews, permitting and commissioning. Our technical knowledge and engineering depth is second to none in flat roof PV and results in a competitive advantage for our customers. We help you win! Contact us and experience all that is PanelClaw on your next flat roof project. PanelClaw is headquartered in North Andover, Massachusetts and is part of the Esdec family, with regional partners in Europe and India. For more information visit: www.panelclaw.com

LoCI Controls' real-time, data-driven platform maximizes methane capture and minimizes landfill gas emissions. Combining patented and patent-pending technology, LoCI's system — including the WellWatcher® user interface and wellhead- and header-mounted components: • Increase gas collection over manual tuning • Optimize gas quality and flow • Offer 24/7/365 monitoring of each collection well to maximize methane collection • Reduce operating costs • Maintain gas quality specifications at inlet to plant • Improve site safety by eliminating the need for well tuning in dangerous conditions • Reduce environmental, health, and safety risks LoCI's automated gas collection operations are supported by a team of analysts who monitor the real-time data and respond accordingly to changing atmospheric conditions. On-the-ground technicians provide all required maintenance as well as technical and operational support for customers. The result: maximized gas collection system efficiency and customer-specified landfill gas composition standards met. Founded in 2013 by MIT graduates, LoCI Controls is led by Peter Quigley, CEO and Chairman, a seasoned leader in disruptive energy technologies.

Essess is a technology company based in Boston, Mass., that is focused on helping building owners increase comfort, save money and eliminate energy waste by using a technology that enables energy efficiency analyses on a large scale. Essess uses a combination of a proprietary thermal imaging technology and proprietary analytics capabilities to provide building owners with a compelling, easy-to-read, thermal image that highlights potential fixes to building structures to increase comfort and reduce energy costs. Through this technology, Essess provides a low-cost, scalable and rapidly deployable means of identifying potential sources of leaks, a leading source of energy waste in the building sector. Partners, including utilities and home performance professionals, can use Essess’s thermal imaging technology to engage customers and to drive business by inspiring them to take action.

Bioviida Venture Studio develops rare disease drugs through clinical POC. We are actively seeking to in-license therapeutics with the following characteristics: Indication: Rare diseases (no CNS) Modality: Small molecules, antibodies, peptides, or proteins Stage: Lead Candidate or later (in vivo POC data in relevant disease model)

Syenex is a synbio technology company that provides novel delivery vector to genetic medicine developers. Our goal is to make it easier for developers to design, test, and scale curative cell and gene therapies

AlleyCorp builds and invests in transformative companies for the present and future in New York. We are humbled to partner with brilliant and determined entrepreneurs along the way. Unconstrained by industry, AlleyCorp originates the ideas, hires the early teams, funds, launches, and grows each company, and maintains an integral leadership role from beginning through exit. AlleyCorp companies have collectively raised more than $2B in venture capital and employ thousands of people in New York City and beyond. On the investment side, AlleyCorp is one of the most active early stage funds in New York. Every company we found fuels a stronger foundation for new ideas and entrepreneurs.

As part of our public mission, UC San Francisco strives to translate our scientific discoveries for public use and benefit. Whether it’s a new drug molecule, diagnostic, medical device or digital health application, our goal is to ensure the best new therapies and technologies can make their way to the patient as efficiently and safely as possible.